Vir Biotechnology Inc（VIR）の財務VIRVir Biotechnology Inc

Evaluating the bottom line, Vir Biotechnology, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 30.75%, while the net margin is 33.51%. These profitability ratios, combined with a Return on Equity (ROE) of -26.08%, provide a clear picture of how effectively VIR converts its operational activities into shareholder value.

In the context of the broader market, VIR competes directly with industry leaders such as URGN and TRVI. With a market capitalization of $1.98B, it holds a leading position in the sector. When comparing efficiency, VIR's gross margin of 100.00% stands against URGN's 90.93% and TRVI's N/A. Such benchmarking helps identify whether Vir Biotechnology, Inc. is trading at a premium or discount relative to its financial performance.

Vir Biotechnology has demonstrated a strong financial turnaround with a net income of $80.08 million in Q2 2026, compared to significant losses in previous quarters, indicating improved operational efficiency and revenue generation.